NM28 2746
Alternative Names: NM 28; NM28-2746Latest Information Update: 22 May 2022
At a glance
- Originator Numab
- Developer 3SBio; Numab
- Class Antineoplastics; Immunoglobulin Fv fragments; Immunotherapies; Trispecific antibodies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 08 Apr 2022 Pharmacodynamics data from preclinical study in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 29 Dec 2021 Numab has patents pending worldwide for hetero-dimeric multi-specific antibody formats
- 15 Dec 2021 NM28 2746 licensed to Sunshine Guojian Pharmaceutical in Greater China area, including mainland China, Hong Kong, Macao and Taiwan